BioSpace News Archive

Collaboration joins together Xencor’s modular XmAb engineered protein platforms with UCLA’s expertise in biology to rapidly create and advance potential new medicines

Quarterly net revenues of $144.0 million, representing 45 percent growth versus the fourth quarter 2019 and 9 percent growth versus the third quarter 2020

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that The Healthcare Technology Report announced Chief Executive Officer, Scott Hutton, as one of the Top 25 Biotech CEOs of 2021.

Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development.

Axovia Therapeutics, an innovative gene therapy company developing disease-transformative medicines for ciliopathies, led by renowned researcher Professor Philip Beales, launched today after being in stealth mode for the past year

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 4, 2021 to report its full year 2020 financial results and discuss recent business highlights.

Worldwide Ocaliva ® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year Intercept provides initial 2021 Worldwide Ocaliva Net Sales Guidance of $325 million to $355 million and Non-GAAP Adjusted Operating Expense Guidance of $380 to $410 million FDA interactions remain ongoing regarding newly identified safety signal (NISS) for liver disorder in a subset of PBC patients with cirrhosis;

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced financial results for the fourth quarter and full-year ended December 31, 2020.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in upcoming investor conferences: Cowen 41 st Annual Health Care Conference: a panel discussion will be available live to conference attendees on Wednesday, March 3 at 11:40 a.m. ET. H.C. Wainwright Global Life Sciences Co

Radius Health, Inc., reported its financial results for the fourth quarter ended December 31, 2020 as well as full year 2020 results.